Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
164 questions in 26 reviews · Oral medicine and oral cancer
current versionsNo studies 164 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment Hospital admission (length of stay) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF) Interventions for managing oral submucous fibrosis (2024) · Cochrane | The trials did not measure hospital admission. | 0 studies | No studies |
Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment Participant-reported resumption of normal eating, chewing and speech · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF) Interventions for managing oral submucous fibrosis (2024) · Cochrane | SoF: participant-reported resumption of normal eating, chewing and speech - outcome not reported by included studies. | 0 studies | No studies |
Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment Postoperative discomfort or pain · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF) Interventions for managing oral submucous fibrosis (2024) · Cochrane | The trials did not measure postoperative discomfort or pain. | 0 studies | No studies |
Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment Participant satisfaction · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF) Interventions for managing oral submucous fibrosis (2024) · Cochrane | The trials did not measure participant satisfaction. | 0 studies | No studies |
Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment Improvement in range of jaw movement · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF) Interventions for managing oral submucous fibrosis (2024) · Cochrane | The trials did not measure range of jaw movement. | 0 studies | No studies |
Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment Quality of life · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF) Interventions for managing oral submucous fibrosis (2024) · Cochrane | The trials did not measure quality of life. | 0 studies | No studies |
Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment Direct costs · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF) Interventions for managing oral submucous fibrosis (2024) · Cochrane | The trials did not measure costs. | 0 studies | No studies |
Surgery plus adjuvant radiotherapy vs Chemotherapy (chemoradiotherapy) Disease-free survival · Adults with oral cavity or oropharyngeal cancer · oral cavity Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Disease-free survival: not reported (Iyer 2015). | 0 studies | No studies |
Surgery plus radiotherapy vs Radiotherapy alone Locoregional recurrence · Adults with oral cavity or oropharyngeal cancer Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Locoregional recurrence: not reported. | 0 studies | No studies |
Surgery plus radiotherapy vs Radiotherapy alone Disease-free survival · Adults with oral cavity or oropharyngeal cancer Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Disease-free survival: not reported. | 0 studies | No studies |
Elective radical (comprehensive) neck dissection vs Elective selective neck dissection Locoregional recurrence · Adults with oral cavity cancer Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Locoregional recurrence: not reported. | 0 studies | No studies |
Surgery vs Radiotherapy alone Locoregional recurrence · Adults with oropharyngeal cancer Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Locoregional recurrence: not reported. | 0 studies | No studies |
Surgery plus radiotherapy vs Radiotherapy alone Recurrence · Adults with oral cavity or oropharyngeal cancer Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Recurrence: not reported. | 0 studies | No studies |
Surgery plus adjuvant radiotherapy vs Chemotherapy (chemoradiotherapy) Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Adverse events: not reported for any participants (Iyer 2015). | 0 studies | No studies |
Superselective neck dissection vs Selective neck dissection Total mortality · Adults with oral cavity cancer (tongue or floor of mouth) and clinically negative neck nodes Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Total mortality: not reported. | 0 studies | No studies |
Supraomohyoid neck dissection vs Modified radical neck dissection Disease-free survival · Adults with oral cavity or oropharyngeal cancer Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Disease-free survival: not reported (Guo 2014 reported disease-specific survival, not a review outcome). | 0 studies | No studies |
Surgery plus adjuvant radiotherapy vs Chemotherapy (chemoradiotherapy) Recurrence · Adults with oral cavity or oropharyngeal cancer · oral cavity Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Recurrence: not reported for the oral cancer subgroup (Iyer 2015). | 0 studies | No studies |
Surgery vs Radiotherapy alone Recurrence · Adults with oropharyngeal cancer Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Recurrence: not reported. | 0 studies | No studies |
Superselective neck dissection vs Selective neck dissection Recurrence · Adults with oral cavity cancer (tongue or floor of mouth) and clinically negative neck nodes Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment (2023) · Cochrane | Recurrence: outcome not reported in a usable way in either study. | 0 studies | No studies |
Oral cytology (e.g. OralCDx brush biopsy, CytID) vs Reference standard: examination and clinical evaluation by a physician/clinician with specialist knowledge or training (long-term follow-up accepted for those screened negative) Outcome NR · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance… Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in… (2021) · Cochrane | Oral cytology (e.g. brush biopsy) was added to the list of eligible index tests in this update; no eligible studies evaluated it (evidence gap). | 0 studies | No studies |
COE with blood/salivary (biomarker) analysis vs Reference standard: examination and clinical evaluation by a physician/clinician with specialist knowledge or training (long-term follow-up accepted for those screened negative) Outcome NR · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance… Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in… (2021) · Cochrane | There were no eligible studies evaluating blood or salivary sample analysis (which tests for the presence of biomarkers for OPMD and OSCC). | 0 studies | No studies |
Chemotherapy (any regimen; added to, or compared with, locoregional treatment) vs Locoregional treatment and/or an alternative chemotherapy regimen Quality of life · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (2021) · Cochrane | Quality of life was a planned (protocol) outcome but no included trial provided usable quality-of-life data; the protocol was modified to report only survival/response outcomes. | 0 studies | No studies |
Chemotherapy vs Placebo Outcome NR · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (2021) · Cochrane | Types of studies: it was anticipated that there would be no studies comparing chemotherapy with placebo (none were identified). | 0 studies | No studies |
COE with light-based detection (e.g. ViziLite Plus, Microlux/DL, VELscope, Identafi 3000) vs COE with vital rinsing (toluidine blue/tolonium chloride) Outcome NR · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance… Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in… (2021) · Cochrane | No eligible studies; planned comparative analysis (COE with vital rinse vs COE with light-based detection) not populated in this version. | 0 studies | No studies |
Blood and saliva analysis (biomarker tests) vs Surgical or punch biopsy with histological assessment Outcome NR · Adults (aged 16 years or over) presenting to primary or secondary care with clinically evident suspicious or innocuous… Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically… (2021) · Cochrane | No eligible studies assessed the diagnostic test accuracy of blood and saliva analysis; potentially eligible biomarker studies were excluded as case-control designs. | 0 studies | No studies |
COE with blood/salivary (biomarker) analysis vs COE with vital rinsing (toluidine blue/tolonium chloride) Outcome NR · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance… Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in… (2021) · Cochrane | No eligible studies; planned comparative analysis (COE with vital rinse vs COE with blood/salivary analysis) not populated in this version. | 0 studies | No studies |
COE with blood/salivary (biomarker) analysis vs Conventional oral examination (COE) alone Outcome NR · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance… Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in… (2021) · Cochrane | No eligible studies; planned comparative analysis (COE vs COE with blood/salivary analysis) not populated in this version. | 0 studies | No studies |
COE with light-based detection (e.g. ViziLite Plus, Microlux/DL, VELscope, Identafi 3000) vs Reference standard: examination and clinical evaluation by a physician/clinician with specialist knowledge or training (long-term follow-up accepted for those screened negative) Outcome NR · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance… Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in… (2021) · Cochrane | There were no eligible studies evaluating light-based detection. | 0 studies | No studies |
COE with light-based detection (e.g. ViziLite Plus, Microlux/DL, VELscope, Identafi 3000) vs Conventional oral examination (COE) alone Outcome NR · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance… Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in… (2021) · Cochrane | No eligible studies; planned comparative analysis (COE vs COE with light-based detection) not populated in this version. | 0 studies | No studies |
COE with vital rinsing (toluidine blue/tolonium chloride) vs Reference standard: examination and clinical evaluation by a physician/clinician with specialist knowledge or training (long-term follow-up accepted for those screened negative) Outcome NR · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance… Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in… (2021) · Cochrane | No eligible study evaluated COE with vital rinse as a stand-alone screen against the reference standard in this version. | 0 studies | No studies |
COE with blood/salivary (biomarker) analysis vs COE with light-based detection (e.g. ViziLite Plus, Microlux/DL, VELscope, Identafi 3000) Outcome NR · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance… Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in… (2021) · Cochrane | No eligible studies; planned comparative analysis (COE with light-based detection vs COE with blood/salivary analysis) not populated in this version. | 0 studies | No studies |
Topical triamcinolone acetonide vs Topical tacrolimus Pain resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment · 3-8 weeks Interventions for treating oral lichen planus: corticosteroid therapies (2020) · Cochrane | Summary of findings 2: 'No data for this outcome' (triamcinolone vs tacrolimus, pain resolution) | 0 studies | No studies |
Mechanical tongue cleaning (tongue scraper) vs No tongue cleaning Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 2 weeks Interventions for managing halitosis (2019) · Cochrane | Adverse events: listed in the Summary of findings table but no data reported. No data were reported for adverse events. | 0 studies | No studies |
Mechanical tongue cleaning (tongue scraper) vs No tongue cleaning Patient-reported OLT score · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 2 weeks Interventions for managing halitosis (2019) · Cochrane | Patient-reported OLT score assessed with patient's perception: listed in the Summary of findings table but no data reported. No data were reported for patient-reported OLT score. | 0 studies | No studies |
0.3% triclosan + PVM/MA + sodium fluoride toothpaste vs Sodium fluoride (control) toothpaste Patient-reported OLT score · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 1 week Interventions for managing halitosis (2019) · Cochrane | Patient-reported OLT score: listed in the Summary of findings table but no data reported. No data were reported for patient-reported OLT score. | 0 studies | No studies |
Hinokitiol gel vs Placebo gel Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 4 weeks Interventions for managing halitosis (2019) · Cochrane | Adverse events: listed in the Summary of findings table but no data reported. No data were reported for adverse events. | 0 studies | No studies |
Chlorhexidine + zinc acetate mouthwash vs Placebo mouthwash Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 3 months Interventions for managing halitosis (2019) · Cochrane | Adverse events: listed in the Summary of findings table but no data reported. No data were reported for adverse events. | 0 studies | No studies |
0.6% eucalyptus chewing gum vs Placebo chewing gum Patient-reported OLT score · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 4 weeks Interventions for managing halitosis (2019) · Cochrane | Patient-reported OLT score: listed in the Summary of findings table but no data reported. No data were reported for patient-reported OLT score. | 0 studies | No studies |
1000 mg champignon extract vs Placebo Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 2 weeks Interventions for managing halitosis (2019) · Cochrane | Adverse events: listed in the Summary of findings table but no data reported. No data were reported for adverse events. | 0 studies | No studies |
Mechanical tongue cleaning (tongue scraper) vs No tongue cleaning Quality of life · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… Interventions for managing halitosis (2019) · Cochrane | Quality of life was a prespecified secondary outcome. None of the 44 included studies in the review (across all comparisons) reported quality-of-life data (review-wide evidence gap). | 0 studies | No studies |
Hinokitiol gel vs Placebo gel Patient-reported OLT score · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 4 weeks Interventions for managing halitosis (2019) · Cochrane | Patient-reported OLT score: listed in the Summary of findings table but no data reported. No data were reported for patient-reported OLT score. | 0 studies | No studies |
Chlorhexidine + zinc acetate mouthwash vs Placebo mouthwash Patient-reported OLT score · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 3 months Interventions for managing halitosis (2019) · Cochrane | Patient-reported OLT score: listed in the Summary of findings table but no data reported. No data were reported for patient-reported OLT score. | 0 studies | No studies |
1000 mg champignon extract vs Placebo Dentist-reported OLT score · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 2 weeks Interventions for managing halitosis (2019) · Cochrane | Dentist-reported OLT score: listed in the Summary of findings table but no data reported. No data were reported for dentist-reported OLT score. | 0 studies | No studies |
Toothbrushing + 0.075% cetylpyridinium chloride mouthwash vs Toothbrushing Patient-reported OLT score · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 3 weeks Interventions for managing halitosis (2019) · Cochrane | Patient-reported OLT score: listed in the Summary of findings table but no data reported. No data were reported for patient-reported OLT score. | 0 studies | No studies |
0.6% eucalyptus chewing gum vs Placebo chewing gum Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 4 weeks Interventions for managing halitosis (2019) · Cochrane | Adverse events: listed in the Summary of findings table but no data reported. No data were reported for adverse events. | 0 studies | No studies |
Toothbrushing + 0.075% cetylpyridinium chloride mouthwash vs Toothbrushing Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 3 weeks Interventions for managing halitosis (2019) · Cochrane | Adverse events: listed in the Summary of findings table but no data reported. No data were reported for adverse events. | 0 studies | No studies |
0.3% triclosan + PVM/MA + sodium fluoride toothpaste vs Sodium fluoride (control) toothpaste Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced… · mean 1 week Interventions for managing halitosis (2019) · Cochrane | Adverse events: listed in the Summary of findings table but no data reported. No data were reported for adverse events. | 0 studies | No studies |
Polaprezinc vs Azulene oral rinse Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy (2017) · Cochrane | No data on salivary flow rates were reported. | 0 studies | No studies |
Polaprezinc vs Azulene oral rinse Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy (2017) · Cochrane | No data on adverse events were reported. | 0 studies | No studies |
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Placebo Number of days unable to take medicine orally · Adults with cancer receiving treatment Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and… (2017) · Cochrane | No studies reported this outcome (planned secondary outcome not measured by any study in the review) | 0 studies | No studies |